突发利空！002581，将被ST

Core Viewpoint - Unimed Pharmaceutical is facing significant operational challenges due to the suspension of its core subsidiary, Tianjin Unimed Biopharmaceutical Co., Ltd, which is expected to impact 60% of the company's revenue [5][6][12]. Group 1: Company Operations - Tianjin Unimed has been suspended from production and sales since April 22, 2024, due to non-compliance with drug production quality management standards [6][9]. - The expected recovery timeline for Tianjin Unimed's operations has been extended, with a new estimate indicating that normal production will not resume until July 21, 2025 [8]. - The suspension has triggered a chain reaction in the procurement market, with several regions halting purchases of interferon products produced by Tianjin Unimed [9]. Group 2: Financial Impact - In 2024, Tianjin Unimed generated revenue of 217 million yuan, accounting for 60.09% of Unimed Pharmaceutical's total revenue and 9.8% of its consolidated net profit [6]. - Unimed Pharmaceutical has reported continuous losses over the past three years, with net profits of -14.68 million yuan in 2022, -332 million yuan in 2023, and -137 million yuan in 2024 [12]. - The company's first-quarter performance in 2024 showed a revenue decline of 57.84% year-on-year, with a net profit of -36.85 million yuan, down 33.01% [12]. Group 3: Regulatory and Compliance Issues - Unimed Pharmaceutical has faced long-standing internal control risks, including failure to disclose related party transactions and inaccurate earnings forecasts [11]. - The company has been penalized by the China Securities Regulatory Commission for various compliance failures, resulting in fines and a 10-year market ban for its former chairman [11].